Terms: = Bone cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Staging
6 results:
1. Prognostic value of RGS1 and mtor Immunohistochemical expression in Egyptian multiple myeloma patients; A single center study.
Hafez N; Refaat L; ElGebaly OK; Elhariry HM; Ghareeb M; Fathalla LA
PLoS One; 2023; 18(7):e0288357. PubMed ID: 37437037
[TBL] [Abstract] [Full Text] [Related]
2. Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.
Stachyra K; Dudzisz-Śledź M; Bylina E; Szumera-Ciećkiewicz A; Spałek MJ; Bartnik E; Rutkowski P; Czarnecka AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208339
[TBL] [Abstract] [Full Text] [Related]
3. NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K/AKT/mtor Pathway.
Li A; Li X; Chen X; Zeng C; Wang Z; Li Z; Chen J
DNA Cell Biol; 2020 Mar; 39(3):368-378. PubMed ID: 31971825
[TBL] [Abstract] [Full Text] [Related]
4. [Expression of mtor and 4E-BP1 in extranodal Nasal-type NK/T-cell Lymphoma and implication for prognosis].
Zhang Q; Liu G; Hang W
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Feb; 33(2):123-127. PubMed ID: 30808136
[No Abstract] [Full Text] [Related]
5. RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast cancer Patients.
Keup C; Mach P; Aktas B; Tewes M; Kolberg HC; Hauch S; Sprenger-Haussels M; Kimmig R; Kasimir-Bauer S
Clin Chem; 2018 Jul; 64(7):1054-1062. PubMed ID: 29769179
[TBL] [Abstract] [Full Text] [Related]
6. 18F-FDG PET/CT in the staging and Management of Breast cancer: Value in Disease Outcome and Planning Therapy.
Garcia JR; Pérez C; Bassa P; Capdevila L; Ramos F; Valenti V
Clin Nucl Med; 2017 Mar; 42(3):191-192. PubMed ID: 28045731
[TBL] [Abstract] [Full Text] [Related]
